遗传性眼病细胞疗法方向博士研究员

PhD in cell therapy for hereditary eye diseases: A vision for the future

Amsterdam UMC · 荷兰 · Amsterdam

原帖优先:申请材料、截止时间与资格以原帖和学校官方说明为准。

AI 中文速览

研究内容
在为期四年的博士项目中,您将开发并表征用于遗传性视网膜疾病(包括回旋状脉络膜视网膜萎缩症和视网膜色素变性)的体外和体内患者来源临床前模型,研究疾病机制并评估细胞疗法的潜力。
申请条件
原文未说明具体学位或背景要求,主要职责为培养患者来源的干细胞、开发分化方案、表征体外及体内模型并进行临床前移植评估。
待遇
月薪在 3217 至 4077 欧元之间,项目期限为四年。
申请方式
原文未说明具体的申请方式、截止日期或提交地址。

由 gemini-2.5-flash-lite 生成,博士岗判定置信度 100%。

岗位信息

截止
(Europe/Amsterdam) 今天截止
学科
生命科学
合同类型
雇佣合同
原文薪资
EUR 3,217–4,077 / 月(税前)
税后月薪(估)
¥19,100–¥24,200;房租后 ¥11,200–¥16,300
估算假设
单身、无子女、雇佣合同的粗略估算,以学校 offer 为准;扣除率 25%;汇率日期 2026-10-01
原帖发布
本站收录
内容更新
来源
AcademicTransfer(荷兰学术招聘) · 最近核对 2026-11-22
详情核验
判定依据(原文摘录)
  • english_ok
    Lifelong VISION, a Gravitation project funded by the Dutch Ministry of Education, Culture and Science (2024-2033), will develop new treatments against blindness.
原文

Developing new treatments starts with models that accurately reflect the disease in the patient. In this four-year PhD project, you will develop and characterize new patient-based preclinical models, both in vitro and in vivo, for inherited retinal diseases, including gyrate atrophy and retinitis pigmentosa. Using these models, you will investigate disease mechanisms and evaluate the potential of cell therapy.

You will work with patient-derived stem cells and develop and optimize differentiation protocols for relevant retinal cell types and tissue models. You will characterize how patients' genetic and clinical characteristics are reflected in the morphology, molecular properties and function of these models. In addition, you will work on the development and characterization of patient-based in vivo models. By connecting findings from cell and tissue models, in vivo models and clinical practice, you will investigate which models and outcome measures are suitable for evaluating new treatments.

These model systems will subsequently form the basis for preclinical cell therapy research. You will investigate how stem cell-derived cells and biomaterials can be combined to create transplantable cell constructs and evaluate their survival, integration and function after transplantation.

The project connects Platform A: Model systems and Pillar 3: Cell-based therapy of the Lifelong VISION consortium . The development of relevant disease models and the development of cell therapy therefore go hand in hand. Through the Emma Center for Personalized Medicine (Emma CPM) , the research aligns with the broader ambition of connecting diagnostics and therapy development for rare hereditary diseases.

Lifelong VISION, a Gravitation project funded by the Dutch Ministry of Education, Culture and Science (2024-2033), will develop new treatments against blindness.

Blindness is among the top 15 most disabling conditions and can manifest in many different ways. In young people, a hereditary retinal condition is the main cause, while in the elderly, age-related macular degeneration is a prominent reason. The Lifelong VISION program is developing a new generation of treatment strategies to prevent blindness: genetic therapies, treatments that target the disease pathways, and cell therapies. State of the art cell and animal models will be developed to test these new therapies in vitro and in vivo. The suitability of each patient group, and the optimal timing for therapeutic intervention is predicted using artificial intelligence, so that the right patient receives the right treatment at the right time. The innovative technologies and strategies developed for eye diseases within our project may serve as blueprints for other diseases and organs.

Ten research institutions participate in the Lifelong Vision project. The project is led by prof. dr. Caroline Klaver from Radboudumc and Erasmus MC; other institutions include Amsterdam UMC, University of Twente, Hubrecht Institute, Eindhoven University of Technology, University of Amsterdam, Utrecht University, Tilburg University, and Netherlands Institute for Neuroscience.

Would you like to know more about the different phases within the PhD trajectory? You can read more about this on this page .

Your main responsibility will be to develop, characterize and apply patient-based preclinical models. In doing so, you will work closely with researchers from Human genetics and clinicians from the Emma Children's Hospital and the department of Ophthalmology at Amsterdam UMC. Together, you will translate clinical questions into experiments and discuss what the results mean for understanding disease mechanisms and developing new treatments.

Your tasks will include: • culturing patient-derived stem cells and developing and optimizing differentiation protocols for retinal cell and tissue models. • characterizing new in vitro models at the molecular, cellular and functional levels and investigating the extent to which they reflect characteristics of the disease; • contributing to the development and characterization of patient-based in vivo models and establishing relevant outcome measures for disease progression and treatment; • applying the models to investigate cell therapy, including combining stem cell-derived cells with biomaterials and performing and evaluating preclinical transplantations; • integrating experimental findings with genetic and clinical patient data, in collaboration with researchers and clinicians; • presenting your results within Lifelong VISION, Emma CPM and at scientific meetings, and incorporating them into scientific publications and a PhD thesis.

信息有误?提交纠错